Posttraumatic Stress Symptom Severity and Marijuana Use Coping Motives: A Test of the Mediating Role of Non-Judgmental Acceptance within a Trauma-Exposed Community Sample.

/by

Authors: Marcel O. Bonn-Miller, Anka A. Vujanovic, Michael P. Twohig, Johnna L. Medina, Jennifer L. Huggins Published in Mindfulness 25 May 2010   Abstract We examined the role of non-judgmental…

Read more

The CB(2) cannabinoid receptor regulates human sperm cell motility.

/by

Authors: Ekaitz Agirregoitia, Arkaitz Carracedo, Nerea Subirán, Asier Valdivia, et al
Fertility and Sterility, 15 March 2010
—
OBJECTIVE: To analyze the expression and distribution of cannabinoid receptors in human sperm cells and evaluate the effects of activation of receptors by specific agonists and antagonists, with a special emphasis on the CB(2) receptor. DESIGN: We performed expression assays f…

Read more

Functional role of cannabinoid receptors in urinary bladder.

/by

Authors: Pradeep Tyagi, Vikas Tyagi, Naoki Yoshimura, Michael Chancellor
Indian Journal of Urology, January-March 2010
—
Cannabinoids, the active components of Cannabis sativa (maijuana), and their derivatives produce a wide spectrum of central and peripheral effects, some of which may have clinical applications. The discovery of specific cannabinoid receptors and a family of endogenous ligands…

Read more

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

/by

Authors: Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, et al
Molecular Cancer Therapeutics, January 2010
—
The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma. It has bee…

Read more

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

/by

Authors: Francesca Borrelli, Gabriella Aviello, Barbara Romano, Pierangelo Orlando, et al
Journal of Molecular Medicine, November 2009
—
Inflammatory bowel disease affects millions of individuals; nevertheless, pharmacological treatment is disappointingly unsatisfactory. Cannabidiol, a safe and non-psychotropic ingredient of marijuana, exerts pharmacological effects (e.g., antioxidant) and mechanisms (e.g., inh…

Read more

If cannabis caused schizophrenia–how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations.

/by

Authors: Matt Hickman, Peter Vickerman, John Macleod, Glyn Lewis, Stan Zammit, et al
Addiction, November 2009
—
BACKGROUND: We consider how many cannabis users may need to be prevented in order to prevent one case of schizophrenia or psychosis [defined as number needed to prevent (NNP)]. METHOD: Calculation for England and Wales using best available estimates of: incidence of schizophre…

Read more

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

/by

Authors: Zahida Qamri, Anju Preet, Mohd W. Nasser, Caroline E. Bass, Gustavo Leone, et al
Molecular Cancer Therapeutics, November 2009
—
Cannabinoids have been reported to possess antitumorogenic activity. Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis. We have shown that the cannabinoid receptors CB1 and CB2 ar…

Read more

Cannabinoids for Tourette’s Syndrome.

/by

Authors: Adrienne Curtis, Carl E Clarke, Hugh E Rickards
Cochrane Database of Systematic Reviews, 7 October 2009
—
BACKGROUND: Gilles de la Tourette Syndrome (GTS) is a developmental neuropsychiatric disorder characterised by the presence of chronic motor and phonic tics. Drugs currently used in the treatment of GTS either lack efficacy or are associated with intolerable side effects. Ther…

Read more

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

/by

Authors: N. Olea-Herrero, D. Vara, S. Malagarie-Cazenave, I. Díaz-Laviada
British Journal of Cancer, 15 September 2009
—
BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti…

Read more

Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005.

/by

Authors: Martin Frisher, Ilana Crome, Orsolina Martino, Peter Croft
Schizophrenia Research, September 2009
—
A recent systematic review concluded that cannabis use increases risk of psychotic outcomes independently of confounding and transient intoxication effects. Furthermore, a model of the association between cannabis use and schizophrenia indicated that the incidence and prevalen…

Read more

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.

/by

Authors: Tamás Bíró, Balázs I. Tóth, György Haskó, Ralf Paus, Pál Pacher
Trends in Pharmacological Sciences, August 2009
—
The newly discovered endocannabinoid system (ECS; comprising the endogenous lipid mediators endocannabinoids present in virtually all tissues, their G-protein-coupled cannabinoid receptors, biosynthetic pathways and metabolizing enzymes) has been implicated in multiple regulat…

Read more

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

/by

Authors: Glenn Schwarcz, Basawaraj Karajgi, Richard McCarthy
Journal of Clinical Psychopharmacology, June 2009
—
We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. I…

Read more